Logo image of GRAL

GRAIL INC (GRAL) Stock Fundamental Analysis

NASDAQ:GRAL - Nasdaq - US3847471014 - Common Stock - Currency: USD

40.73  -7.03 (-14.72%)

After market: 40.15 -0.58 (-1.42%)

Fundamental Rating

3

Taking everything into account, GRAL scores 3 out of 10 in our fundamental rating. GRAL was compared to 571 industry peers in the Biotechnology industry. GRAL has a great financial health rating, but its profitability evaluates not so good. GRAL is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

GRAL had negative earnings in the past year.
GRAL Yearly Net Income VS EBIT VS OCF VS FCFGRAL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2021 2022 2023 -1B -2B -3B -4B -5B

1.2 Ratios

With a Return On Assets value of -108.91%, GRAL is not doing good in the industry: 78.15% of the companies in the same industry are doing better.
The Return On Equity of GRAL (-131.22%) is worse than 61.81% of its industry peers.
Industry RankSector Rank
ROA -108.91%
ROE -131.22%
ROIC N/A
ROA(3y)-53.2%
ROA(5y)N/A
ROE(3y)-56.54%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GRAL Yearly ROA, ROE, ROICGRAL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

Looking at the Gross Margin, with a value of 42.47%, GRAL is in the better half of the industry, outperforming 76.73% of the companies in the same industry.
GRAL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 42.47%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GRAL Yearly Profit, Operating, Gross MarginsGRAL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2021 2022 2023 0 -2K -4K -6K -8K

More info and screens

7

2. Health

2.1 Basic Checks

GRAL does not have a ROIC to compare to the WACC, probably because it is not profitable.
GRAL has about the same amout of shares outstanding than it did 1 year ago.
There is no outstanding debt for GRAL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GRAL Yearly Shares OutstandingGRAL Yearly Shares OutstandingYearly Shares Outstanding 2019 2021 2022 2023 20M 40M 60M 80M 100M
GRAL Yearly Total Debt VS Total AssetsGRAL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2021 2022 2023 2B 4B 6B 8B

2.2 Solvency

GRAL has an Altman-Z score of -3.68. This is a bad value and indicates that GRAL is not financially healthy and even has some risk of bankruptcy.
GRAL has a Altman-Z score (-3.68) which is comparable to the rest of the industry.
There is no outstanding debt for GRAL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.68
ROIC/WACCN/A
WACC9.52%
GRAL Yearly LT Debt VS Equity VS FCFGRAL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2021 2022 2023 0 2B 4B 6B 8B

2.3 Liquidity

A Current Ratio of 9.65 indicates that GRAL has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 9.65, GRAL is in the better half of the industry, outperforming 79.40% of the companies in the same industry.
A Quick Ratio of 9.65 indicates that GRAL has no problem at all paying its short term obligations.
With a decent Quick ratio value of 9.65, GRAL is doing good in the industry, outperforming 79.57% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.65
Quick Ratio 9.65
GRAL Yearly Current Assets VS Current LiabilitesGRAL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 72.85% over the past year.
GRAL shows a strong growth in Revenue. In the last year, the Revenue has grown by 67.61%.
EPS 1Y (TTM)72.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)67.61%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 19.94% on average over the next years. This is quite good.
Based on estimates for the next years, GRAL will show a very strong growth in Revenue. The Revenue will grow by 20.95% on average per year.
EPS Next Y-23.16%
EPS Next 2Y29.33%
EPS Next 3Y19.94%
EPS Next 5YN/A
Revenue Next Year35.17%
Revenue Next 2Y25.68%
Revenue Next 3Y20.95%
Revenue Next 5YN/A

3.3 Evolution

GRAL Yearly Revenue VS EstimatesGRAL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2021 2022 2023 2024 2025 2026 50M 100M 150M
GRAL Yearly EPS VS EstimatesGRAL Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2021 2022 2023 2024 2025 2026 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GRAL. In the last year negative earnings were reported.
Also next year GRAL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GRAL Price Earnings VS Forward Price EarningsGRAL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GRAL Per share dataGRAL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 50 -50 -100

4.3 Compensation for Growth

A more expensive valuation may be justified as GRAL's earnings are expected to grow with 19.94% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.33%
EPS Next 3Y19.94%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GRAL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GRAIL INC

NASDAQ:GRAL (2/21/2025, 8:24:26 PM)

After market: 40.15 -0.58 (-1.42%)

40.73

-7.03 (-14.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-20 2025-02-20/amc
Earnings (Next)N/A N/A
Inst Owners78.78%
Inst Owner Change16.59%
Ins Owners0.17%
Ins Owner Change12.81%
Market Cap1.37B
Analysts47.5
Price Target16.32 (-59.93%)
Short Float %18.31%
Short Ratio4.28
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)7.39%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.55%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)8.18%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)2.03%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.58
P/FCF N/A
P/OCF N/A
P/B 0.53
P/tB 2.55
EV/EBITDA N/A
EPS(TTM)-118.45
EYN/A
EPS(NY)-18.07
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS5.37
BVpS77.01
TBVpS15.96
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -108.91%
ROE -131.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 42.47%
FCFM N/A
ROA(3y)-53.2%
ROA(5y)N/A
ROE(3y)-56.54%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.65
Quick Ratio 9.65
Altman-Z -3.68
F-ScoreN/A
WACC9.52%
ROIC/WACCN/A
Cap/Depr(3y)47.51%
Cap/Depr(5y)N/A
Cap/Sales(3y)177.85%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-23.16%
EPS Next 2Y29.33%
EPS Next 3Y19.94%
EPS Next 5YN/A
Revenue 1Y (TTM)67.61%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year35.17%
Revenue Next 2Y25.68%
Revenue Next 3Y20.95%
Revenue Next 5YN/A
EBIT growth 1Y-7.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-162.48%
EBIT Next 3Y15.65%
EBIT Next 5YN/A
FCF growth 1Y-4.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6.14%
OCF growth 3YN/A
OCF growth 5YN/A